[ad_1]
And late on Wednesday night, the Fifth US Circuit Court of appeals agreed, saying the FDA’s decades-old approval of mifepristone should stand, because too much time had passed to challenge that decision. But the appellate panel decided to roll back several changes made by the FDA starting in 2016 that eased access to the drug.
[ad_2]
Source link